Literature DB >> 15899789

Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background.

Julien Ackermann1, Manon Frutschi, Kostas Kaloulis, Thomas McKee, Andreas Trumpp, Friedrich Beermann.   

Abstract

In human cutaneous malignant melanoma, a predominance of activated mutations in the N-ras gene has been documented. To obtain a mouse model most closely mimicking the human disease, a transgenic mouse line was generated by targeting expression of dominant-active human N-ras (N-RasQ61K) to the melanocyte lineage by tyrosinase regulatory sequences (Tyr::N-RasQ61K). Transgenic mice show hyperpigmented skin and develop cutaneous metastasizing melanoma. Consistent with the tumor suppressor function of the INK4a locus that encodes p16INK4A and p19(ARF), >90% of Tyr::N-RasQ61K INK4a-/- transgenic mice develop melanoma at 6 months. Primary melanoma tumors are melanotic, multifocal, microinvade the epidermis or epithelium of hair follicles, and disseminate as metastases to lymph nodes, lung, and liver. Primary melanoma can be transplanted s.c. in nude mice, and if injected i.v. into NOD/SCID mice colonize the lung. In addition, primary melanomas and metastases contain cells expressing the stem cell marker nestin suggesting a hierarchical structure of the tumors comprised of primitive nestin-expressing precursors and differentiated cells. In conclusion, a novel mouse model with melanotic and metastasizing melanoma was obtained by recapitulating genetic lesions frequently found in human melanoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899789     DOI: 10.1158/0008-5472.CAN-04-2970

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  114 in total

1.  Beta-catenin inhibits melanocyte migration but induces melanoma metastasis.

Authors:  S J Gallagher; F Rambow; M Kumasaka; D Champeval; A Bellacosa; V Delmas; L Larue
Journal:  Oncogene       Date:  2012-06-04       Impact factor: 9.867

Review 2.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 3.  Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.

Authors:  Gajanan S Inamdar; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Biochem Pharmacol       Date:  2010-05-09       Impact factor: 5.858

4.  LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.

Authors:  Wenjin Liu; Kimberly B Monahan; Adam D Pfefferle; Takeshi Shimamura; Jessica Sorrentino; Keefe T Chan; David W Roadcap; David W Ollila; Nancy E Thomas; Diego H Castrillon; C Ryan Miller; Charles M Perou; Kwok-Kin Wong; James E Bear; Norman E Sharpless
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

Review 5.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

6.  Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma.

Authors:  Olga Shakhova; Daniel Zingg; Simon M Schaefer; Lisette Hari; Gianluca Civenni; Jacqueline Blunschi; Stéphanie Claudinot; Michal Okoniewski; Friedrich Beermann; Daniela Mihic-Probst; Holger Moch; Michael Wegner; Reinhard Dummer; Yann Barrandon; Paolo Cinelli; Lukas Sommer
Journal:  Nat Cell Biol       Date:  2012-07-08       Impact factor: 28.824

Review 7.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

8.  TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression.

Authors:  Elise Bonvin; Enrico Radaelli; Martin Bizet; Flavie Luciani; Emilie Calonne; Pascale Putmans; David Nittner; Nitesh Kumar Singh; Sara Francesca Santagostino; Valérie Petit; Lionel Larue; Jean Christophe Marine; François Fuks
Journal:  Cancer Res       Date:  2018-12-11       Impact factor: 12.701

9.  Wnt signaling potentiates nevogenesis.

Authors:  Jeff S Pawlikowski; Tony McBryan; John van Tuyn; Mark E Drotar; Rachael N Hewitt; Andrea B Maier; Ayala King; Karen Blyth; Hong Wu; Peter D Adams
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

10.  Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish.

Authors:  Michael Dovey; Richard Mark White; Leonard I Zon
Journal:  Zebrafish       Date:  2009-12       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.